BTG plc (LON:BTG) had its target price increased by research analysts at JPMorgan Chase & Co. from GBX 790 ($10.31) to GBX 830 ($10.83) in a research report issued to clients and investors on Friday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price indicates a potential upside of 18.32% from the stock’s current price.

A number of other research firms also recently issued reports on BTG. Numis Securities Ltd reissued a “hold” rating and issued a GBX 737 ($9.62) price objective on shares of BTG plc in a report on Thursday. Deutsche Bank AG reissued a “buy” rating on shares of BTG plc in a report on Thursday, September 8th. Jefferies Group reissued a “buy” rating and issued a GBX 860 ($11.23) price objective on shares of BTG plc in a report on Friday, July 15th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of BTG plc in a report on Friday, June 24th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of GBX 799.57 ($10.44).

Analyst Recommendations for BTG plc (LON:BTG)

BTG plc (LON:BTG) traded up 2.56% on Friday, reaching GBX 701.50. 980,141 shares of the company traded hands. The company’s market capitalization is GBX 2.69 billion. The stock’s 50 day moving average price is GBX 629.82 and its 200 day moving average price is GBX 641.22. BTG plc has a one year low of GBX 504.00 and a one year high of GBX 739.50.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other news, insider Soderstrom,Rolf sold 74,327 shares of the business’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of GBX 676 ($8.82), for a total value of £502,450.52 ($655,855.01).

About BTG plc

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with's FREE daily email newsletter.